Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 1
2010 1
2012 2
2013 2
2014 3
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

PubMed for Bookshelf ID: 4867296

10 results

Results by year

Filters applied: . Clear all
Page 1
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID; SIRIUS Investigators. Bel EH, et al. N Engl J Med. 2014 Sep 25;371(13):1189-97. doi: 10.1056/NEJMoa1403291. Epub 2014 Sep 8. N Engl J Med. 2014. PMID: 25199060 Free article. Clinical Trial.
Mepolizumab treatment in patients with severe eosinophilic asthma.
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, Chanez P; MENSA Investigators. Ortega HG, et al. N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8. N Engl J Med. 2014. PMID: 25199059 Free article. Clinical Trial.
Drugs for asthma and COPD.
[No authors listed] [No authors listed] Treat Guidel Med Lett. 2013 Aug;11(132):75-86; quiz following 86. Treat Guidel Med Lett. 2013. PMID: 23896773 No abstract available.
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes.
Roufosse FE, Kahn JE, Gleich GJ, Schwartz LB, Singh AD, Rosenwasser LJ, Denburg JA, Ring J, Rothenberg ME, Sheikh J, Haig AE, Mallett SA, Templeton DN, Ortega HG, Klion AD. Roufosse FE, et al. J Allergy Clin Immunol. 2013 Feb;131(2):461-7.e1-5. doi: 10.1016/j.jaci.2012.07.055. Epub 2012 Oct 4. J Allergy Clin Immunol. 2013. PMID: 23040887 Free PMC article. Clinical Trial.
Mepolizumab and exacerbations of refractory eosinophilic asthma.
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID. Haldar P, et al. N Engl J Med. 2009 Mar 5;360(10):973-84. doi: 10.1056/NEJMoa0808991. N Engl J Med. 2009. PMID: 19264686 Free PMC article. Clinical Trial.
Treatment of patients with the hypereosinophilic syndrome with mepolizumab.
Rothenberg ME, Klion AD, Roufosse FE, Kahn JE, Weller PF, Simon HU, Schwartz LB, Rosenwasser LJ, Ring J, Griffin EF, Haig AE, Frewer PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group. Rothenberg ME, et al. N Engl J Med. 2008 Mar 20;358(12):1215-28. doi: 10.1056/NEJMoa070812. Epub 2008 Mar 16. N Engl J Med. 2008. PMID: 18344568 Free article. Clinical Trial.